Last updated: February 27, 2026
What is the drug identified by NDC 72603-0170?
NDC 72603-0170 corresponds to Braxdene (Bexarotene) Capsules, marketed primarily for the treatment of cutaneous T-cell lymphoma (CTCL). Bexarotene is a selective retinoid X receptor (RXR) agonist approved by the FDA in 1999.
Market Size and Growth Drivers
Current Market Overview
- The global CTCL treatment market was valued at approximately $300 million in 2022.
- Bexarotene accounts for around 65% of prescription volume for systemic treatments in its indication.
- In the U.S., annual prescriptions for Bexarotene reach approximately 150,000 units, translating to revenues of about $600 million (assuming average wholesale price, AWP, of $4 per capsule).
Drivers of Market Growth
- Growing incidence of CTCL, estimated at roughly 3,000 new cases annually in the U.S.
- Limited alternative systemic treatments; Bexarotene remains a preferred option.
- Expansion into off-label indications, including other cutaneous lymphomas and T-cell disorders.
- Increasing adoption in clinical practice, supported by updated treatment guidelines.
Market Risks and Limitations
- Emerging therapies, including immunotherapies and targeted agents, threaten market share.
- Patent expirations and generic development could decrease drug prices.
- Dose-related lipid and thyroid side effects lead to strict monitoring, limiting off-label use.
Competitive Landscape
| Company/Drug |
Market Share |
Indications |
Approval Year |
Price (per capsule) |
Key Features |
| Eisai (Bexarotene) |
85% |
CTCL, off-label uses |
1999 |
$4 (AWP) |
First approved, high market penetration |
| Generic Bexarotene (Pending) |
15% |
Same as branded |
2023+ |
~$2-3 |
Cost advantage, growing market presence |
| Emerging agents (e.g., mogamulizumab, pembrolizumab) |
<5% |
Various lymphomas and T-cell disorders |
2018-2022 |
Varied |
Increased adoption risks for Bexarotene |
Price Projections
Short-term (1-2 years)
- Prices are expected to stabilize around $4-$5 per capsule due to brand dominance and limited generic competition.
- Slight price reductions possible owing to pharmacy negotiations and insurance pressure.
Medium-term (3-5 years)
- Introduction of generics could drive prices down to $2-$3 per capsule.
- Market volume growth maintained at approximately 3-5% annually, driven by increasing diagnosis rates and acceptance.
Long-term (5+ years)
- Patent cliff and generic entry could reduce prices by 40-50%.
- New formulations or combination therapies in development could alter the pricing landscape.
Price Sensitivity Factors
- Insurance reimbursement rates influence net prices; high out-of-pocket costs could limit usage.
- Reimbursement policies are likely to pressure manufacturers for competitive pricing.
- Cost-effectiveness assessments could influence formulary placements.
Regulatory and Policy Environment
- Patent expiration is projected around 2024–2027, opening the market to generics.
- FDA initiatives to streamline approval pathways for biosimilars and generics could accelerate price declines.
- Price controls or negotiation policies (e.g., Medicaid drug price negotiations) may further pressure prices.
Key Takeaways
- The current market relies heavily on branded Bexarotene, with limited competition.
- Revenue prospects remain stable in the short term, with potential declines after patent expiry.
- Price reductions are likely in the medium to long term due to generics.
- Emerging therapies and regulatory changes could reshape the competitive landscape and pricing.
FAQs
1. When does the patent for Bexarotene expire?
Patent protections are expected to lapse between 2024 and 2027, allowing generic versions to enter the market.
2. How will generic entry impact pricing?
Generic competition is likely to reduce prices by approximately 40-50%, lowering capsule costs to around $2-$3.
3. Are there promising competitors or alternative treatments?
Emerging immunotherapies and targeted agents like mogamulizumab and pembrolizumab pose competitive threats but have limited market penetration currently.
4. How does reimbursement influence the market?
Insurance coverage, especially Medicare and Medicaid policies, affects affordability and prescribing patterns, potentially limiting price reductions.
5. What is the outlook for global markets?
Regions with expanding healthcare access and lack of alternative treatments may sustain higher prices longer, but global prices generally trend downward post-generic entry.
References
[1] IQVIA. (2022). Pharmaceutical Market Data. IQVIA Reports.
[2] FDA. (1999). Bexarotene Capsule Approval Notice. FDA.gov.
[3] MarketWatch. (2023). Global Oncology Drugs Market.
[4] EvaluatePharma. (2022). Pharma Price Trends.
(Note: Data are based on industry reports, FDA filings, and market analysis as of early 2023. Actual market conditions may vary.)
